US FDA gives nod to Endo, ProStrakan testosterone gel
This article was originally published in Scrip
Executive Summary
Endo Pharmaceuticals and its partner ProStrakan have won approval from the US FDA to market their testosterone gel product Fortesta to treat hypogonadism, an often misdiagnosed condition in men in which the body fails to produce normal amounts of testosterone, resulting in fatigue, loss of muscle mass, decreased libido and erectile dysfunction.